Veracyte (VCYT) Competitors $28.61 -0.46 (-1.58%) Closing price 04:00 PM EasternExtended Trading$28.45 -0.16 (-0.56%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VCYT vs. ADPT, BEAM, GH, TWST, TXG, RDNT, OPCH, SHC, BTSG, and WGSShould you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Adaptive Biotechnologies (ADPT), Beam Therapeutics (BEAM), Guardant Health (GH), Twist Bioscience (TWST), 10x Genomics (TXG), RadNet (RDNT), Option Care Health (OPCH), Sotera Health (SHC), BrightSpring Health Services (BTSG), and GeneDx (WGS). These companies are all part of the "medical" sector. Veracyte vs. Its Competitors Adaptive Biotechnologies Beam Therapeutics Guardant Health Twist Bioscience 10x Genomics RadNet Option Care Health Sotera Health BrightSpring Health Services GeneDx Veracyte (NASDAQ:VCYT) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership. Do insiders and institutionals believe in VCYT or ADPT? 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 1.4% of Veracyte shares are owned by company insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate VCYT or ADPT? Veracyte currently has a consensus target price of $40.90, indicating a potential upside of 42.96%. Adaptive Biotechnologies has a consensus target price of $12.38, indicating a potential downside of 4.59%. Given Veracyte's higher possible upside, equities research analysts clearly believe Veracyte is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Is VCYT or ADPT more profitable? Veracyte has a net margin of 5.50% compared to Adaptive Biotechnologies' net margin of -59.07%. Veracyte's return on equity of 6.07% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Veracyte5.50% 6.07% 5.53% Adaptive Biotechnologies -59.07%-60.93%-23.03% Which has more risk & volatility, VCYT or ADPT? Veracyte has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Does the media favor VCYT or ADPT? In the previous week, Adaptive Biotechnologies had 4 more articles in the media than Veracyte. MarketBeat recorded 19 mentions for Adaptive Biotechnologies and 15 mentions for Veracyte. Veracyte's average media sentiment score of 1.05 beat Adaptive Biotechnologies' score of 0.71 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 8 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Adaptive Biotechnologies 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, VCYT or ADPT? Veracyte has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeracyte$445.76M5.05$24.14M$0.3386.70Adaptive Biotechnologies$178.96M11.04-$159.49M-$0.82-15.82 SummaryVeracyte beats Adaptive Biotechnologies on 11 of the 16 factors compared between the two stocks. Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCYT vs. The Competition Export to ExcelMetricVeracyteMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.25B$6.86B$5.74B$9.78BDividend YieldN/A1.29%4.40%4.04%P/E Ratio86.7026.4430.8326.39Price / Sales5.0565.75382.9086.63Price / Cash28.5021.5337.7259.11Price / Book1.846.8510.106.62Net Income$24.14M$176.42M$3.26B$265.42M7 Day Performance-2.98%3.36%3.90%3.58%1 Month Performance13.31%-2.06%3.73%0.46%1 Year Performance-10.59%8.14%37.68%19.41% Veracyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCYTVeracyte2.3978 of 5 stars$28.61-1.6%$40.90+43.0%-10.1%$2.25B$445.76M86.70790Positive NewsADPTAdaptive Biotechnologies2.5115 of 5 stars$12.41-4.8%$12.38-0.3%+166.1%$1.99B$178.96M-15.13790BEAMBeam Therapeutics1.9884 of 5 stars$17.10-4.0%$48.45+183.4%-38.6%$1.80B$63.52M0.00510GHGuardant Health3.2835 of 5 stars$59.47+1.0%$57.50-3.3%+137.2%$7.34B$739.02M-17.752,021Positive NewsTWSTTwist Bioscience4.1213 of 5 stars$28.02-0.4%$49.40+76.3%-37.0%$1.70B$312.97M-19.32990Positive NewsTXG10x Genomics3.8772 of 5 stars$13.46+0.7%$13.54+0.6%-38.5%$1.66B$610.78M-19.231,240Insider TradeRDNTRadNet3.2523 of 5 stars$66.29-1.7%$71.60+8.0%+8.3%$5.19B$1.83B-331.4311,021Positive NewsOPCHOption Care Health4.8447 of 5 stars$28.19-0.5%$35.75+26.8%-11.0%$4.60B$5.00B19.678,088Positive NewsSHCSotera Health1.5379 of 5 stars$15.80+0.4%$16.00+1.3%+5.0%$4.47B$1.10B24.983,000Positive NewsInsider TradeBTSGBrightSpring Health Services1.6882 of 5 stars$23.09+2.9%$25.67+11.2%+88.0%$3.98B$11.27B30.3235,000Positive NewsWGSGeneDx2.1336 of 5 stars$125.90-0.4%$101.63-19.3%+254.7%$3.63B$305.45M2,518.001,200Positive News Related Companies and Tools Related Companies Adaptive Biotechnologies Competitors Beam Therapeutics Competitors Guardant Health Competitors Twist Bioscience Competitors 10x Genomics Competitors RadNet Competitors Option Care Health Competitors Sotera Health Competitors BrightSpring Health Services Competitors GeneDx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCYT) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access